Disease Overview：Leukemia（LEUK）
Leukemia is a heterogeneous group of hematologic malignancies characterized by uncontrolled proliferation and impaired differentiation of hematopoietic stem cells in the bone marrow and peripheral blood. Classified into acute (ALL, AML) and chronic (CLL, CML) subtypes based on disease kinetics and cellular lineage—lymphoid or myeloid—leukemia presents with cytopenias, fatigue, recurrent infections, bleeding tendencies, and organ infiltration. Diagnosis relies on peripheral blood smear, bone marrow aspiration and biopsy, flow cytometry, cytogenetics (e.g., Philadelphia chromosome detection), and molecular profiling (e.g., BCR-ABL1, FLT3, NPM1). Treatment modalities include risk-stratified chemotherapy regimens, targeted therapies (tyrosine kinase inhibitors like imatinib for CML; venetoclax + azacitidine for AML), immunotherapies (blinatumomab, CAR-T for relapsed/refractory ALL), and allogeneic hematopoietic stem cell transplantation (allo-HSCT) for eligible patients. Prognosis varies significantly by subtype, age, genetic profile, and response to induction therapy.
China offers compelling advantages for leukemia care: its top-tier oncology centers—such as Peking University People’s Hospital and Shanghai Ruijin Hospital—rank among Asia’s most experienced in allo-HSCT and minimal residual disease (MRD)-guided therapy, with 5-year overall survival rates for standard-risk ALL exceeding 70% and AML reaching 60–65% in younger adults. Advanced infrastructure includes next-generation sequencing platforms, digital PET-CT, and GMP-certified CAR-T manufacturing facilities. Treatment costs are typically 40–60% lower than in the US or Western Europe without compromising clinical rigor or regulatory compliance (NMPA-approved biologics and generics). As a dedicated medical tourism agency, we facilitate seamless international patient journeys—vetting JCI-accredited hospitals, coordinating multidisciplinary tumor boards, providing transparent all-inclusive pricing, arranging visas and accommodation, and offering bilingual clinical liaison and post-treatment follow-up support.
Leukemia: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Leukemia (Hematology/Oncology)
Non-Surgical/Medical Therapies
*Target Criteria:* Newly diagnosed AML/ALL/CML; relapsed/refractory disease; elderly or comorbid patients unfit for intensive therapy.
- •Chemotherapy (Induction + Consolidation)
- Drug fees: $1,850–$2,600 -45–$65/day × 30 days = $1,350–$1,950 - CBC, peripheral smear, bone marrow biopsy (×2): $320 - Flow cytometry + cytogenetics (karyotype + FISH): $480
- •Targeted Therapy (CML/Ph+ ALL)
- Annual drug cost: $2,100–$2,900 - Monthly PCR monitoring (BCR-ABL): $85 × 12 = $1,020 - Liver/kidney function panels (q3mo): $140 × 0
- •Immunotherapy (Relapsed/Refractory ALL)
- Drug + infusion pump + ICU-level nursing: $14,200–$16,800/cycle - Pre-treatment cytokine panel & neurologic assessment: $290
Surgical/Procedural Interventions
*Eligibility:* Fit patients with high-risk AML/ALL or CML blast crisis; confirmed HLA-matched donor (sibling or unrelated registry).
- •Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
- Conditioning regimen (Flu/Bu or TBI-based):
$3,400–$4,700 - Stem cell infusion + 30-day inpatient care (GVHD prophylaxis, infection control, transfusion support): $28,500–$34,200 - Post-transplant chimerism + MRD monitoring (q1mo × 6): $1,380Special/Complex Condition Management
- •
- ICU-level cytokine release syndrome management (if required):
+$12,500–$18,000Quick Selection Guide
- •
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Leukemia Medical Vacation Packages
Curated transparent all-inclusive packages combining Leukemia treatment with China top medical destinations:
